ABSTRACT
BACKGROUND: Actinic keratosis (AK) usually co-exists in areas of severe photodamage, but the clinical applicability of reflectance confocal microscopy (RCM) in diagnosing AK currently depends on a set of parameters yet to be defined in comparison to photodamaged skin (PD). OBJECTIVE: To correlate the RCM features of PD and AK with histopathology. METHODS: Twenty participants with a mean age of 64 years and skin phototype I and II were studied. RCM was performed on two PD and one AK within a field of 25 cm2 on the left dorsal forearm, followed by shave biopsies. Blinded evaluation of the histopathological and RCM images using established parameters in AK were performed retrospectively in consensus with an expert confocalist, correlated with the histopathological diagnosis by a board-certified dermatopathologist. RESULTS: A total of 57/60 areas were included. There were 43/57 (75%) and 14/57 (25%) histopathologically confirmed PD and AK respectively. Individual corneocytes, stratum corneum disruption, dermal inflammatory cells, increased vascularity/dilated vessels and solar elastosis were detected in PD and AK upon histopathology and RCM. The features in favour of AK were parakeratosis, hyperkeratosis, more severe keratinocyte pleomorphism and architectural disruption, and the presence of epidermal inflammatory cells. PD also demonstrated keratinocyte pleomorphism and architectural disruption though this was generally less severe than AK. A small subset of PD exhibited a comparable degree of keratinocyte pleomorphism and architectural disruption to the AKs in the cohort. CONCLUSIONS: The viable epidermis demonstrates PD and AK to be part of a disease continuum corresponding to field cancerization. Individual corneocytes, stratum corneum disruption, dermal inflammatory cells, increased vascularity/dilated vessels and solar elastosis may be present in PD; whereas, parakeratosis and hyperkeratosis may represent the key to distinguishing AK from PD using RCM. The significance of epidermal inflammatory cells in the RCM diagnosis of AK remains to be elucidated.
Subject(s)
Keratosis, Actinic/pathology , Microscopy, Confocal/methods , Female , Humans , Male , Middle AgedABSTRACT
BACKGROUND: LEO 43204 is a novel ingenol derivative in development for the treatment of actinic keratosis. OBJECTIVES: To compare the safety and preliminary efficacy of three doses of LEO 43204 with ingenol mebutate in actinic keratoses (AKs). METHODS: Patients with at least three visible, discrete, nonkeratotic AKs on four separate selected treatment areas on the forearms received LEO 43204 gel (0·025%, 0·05% and 0·075%) and ingenol mebutate 0·05% gel, by investigator-blinded, randomized allocation, for 2 consecutive days. Patients were assessed at 8 weeks. Primary outcomes included maximum composite local skin response (LSR) score and adverse events (AEs). Secondary outcomes included a reduction in the number of visible AKs. RESULTS: Forty patients completed the trial. For all treatments, mean LSR scores peaked at week 1, and were below baseline by week 8. Mean maximum composite LSR scores for LEO 43204 0·025%, 0·05% and 0·075% were 9·2 (Dunnett adjusted P = 0·02), 10·1 (Dunnett adjusted P = 0·90) and 11·2 (Dunnett adjusted P < 0·01), respectively, vs. ingenol mebutate 0·05% gel (10·0). The most frequent AEs across all treatments were application site pruritus, burning sensation and tenderness. Mean reduction in the number of AKs was comparable for ingenol mebutate and the two lowest doses of LEO 43204 (71·9-73·1%), but LEO 43204 0·075% gave a significantly larger reduction (81·8%; Dunnett adjusted P = 0·04). CONCLUSIONS: LEO 43204 had a similar safety profile to ingenol mebutate and a dose-response relationship for LSRs was demonstrated. The highest LEO 43204 dose (0·075%) significantly reduced the AK count when compared with ingenol mebutate.
Subject(s)
Dermatologic Agents/administration & dosage , Keratosis, Actinic/drug therapy , Administration, Cutaneous , Aged , Aged, 80 and over , Dermatologic Agents/adverse effects , Diterpenes/administration & dosage , Diterpenes/adverse effects , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Treatment OutcomeABSTRACT
BACKGROUND: Nilotinib is a second generation tyrosine kinase inhibitor, used in the treatment of chronic myelogenous leukaemia (CML). METHODS: We assessed a 72-year-old woman who was treated with nilotinib for CML. RESULTS: During the year following commencement of nilotinib, the patient developed eight squamous cell carcinomas (SCCs) on her legs. CONCLUSIONS: Development of SCC is a previously unreported adverse reaction to nilotinib.
Subject(s)
Antineoplastic Agents/adverse effects , Carcinoma, Squamous Cell/chemically induced , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Protein Kinase Inhibitors/adverse effects , Pyrimidines/adverse effects , Skin Neoplasms/chemically induced , Aged , Female , Humans , LegABSTRACT
A two-part prospective study was conducted to assess rates of surgical site infection (SSI) following caesarean section in a large Australian regional hospital before and after a change of timing of antibiotic prophylaxis from after cord clamping to pre-incision. SSI rates dropped from 10.8% in 2010 to 2.8% in 2011 with no adverse neonatal consequences, providing further evidence that antibiotic prophylaxis should be given pre-incision for caesarean section in hospitals in Australia and New Zealand, as is now accepted practice elsewhere.
